Navigation Links
Patient-specific stem cells and personalized gene therapy
Date:7/10/2014

NEW YORK, NY (July 10, 2014) Columbia University Medical Center (CUMC) researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss. The approach, the first of its kind, takes advantage of induced pluripotent stem (iPS) cell technology to transform skin cells into retinal cells, which are then used as a patient-specific model for disease study and preclinical testing.

Using this approach, researchers led by Stephen H. Tsang, MD, PhD, showed that a form of RP caused by mutations to the gene MFRP (membrane frizzled-related protein) disrupts the protein that gives retinal cells their structural integrity. They also showed that the effects of these mutations can be reversed with gene therapy. The approach could potentially be used to create personalized therapies for other forms of RP, as well as other genetic diseases. The paper was published recently in the online edition of Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy.

"The use of patient-specific cell lines for testing the efficacy of gene therapy to precisely correct a patient's genetic deficiency provides yet another tool for advancing the field of personalized medicine," said Dr. Tsang, the Laszlo Z. Bito Associate Professor of Ophthalmology and associate professor of pathology and cell biology.

While RP can begin during infancy, the first symptoms typically emerge in early adulthood, starting with night blindness. As the disease progresses, affected individuals lose peripheral vision. In later stages, RP destroys photoreceptors in the macula, which is responsible for fine central vision. RP is estimated to affect at least 75,000 people in the United States and 1.5 million worldwide.

More than 60 different genes have been linked to RP, making it difficult to develop models to study the disease. Animal models, though useful, have significant limitations because of interspecies differences. Researchers also use human retinal cells from eye banks to study RP. As these cells reflect the end stage of the disease process, however, they reveal little about how the disease develops. There are no human tissue culture models of RP, as it would dangerous to harvest retinal cells from patients. Finally, human embryonic stem cells could be useful in RP research, but they are fraught with ethical, legal, and technical issues.

The use of iPS technology offers a way around these limitations and concerns. Researchers can induce the patient's own skin cells to revert to a more basic, embryonic stem celllike state. Such cells are "pluripotent," meaning that they can be transformed into specialized cells of various types.

In the current study, the CUMC team used iPS technology to transform skin cells taken from two RP patientseach with a different MFRP mutationinto retinal cells, creating patient-specific models for studying the disease and testing potential therapies.

By analyzing these cells, the researchers found that the primary effect of MFRP mutations is to disrupt the regulation of actin, the protein that makes up the cytoskeleton, the scaffolding that gives the cell its structural integrity. "Normally, the cytoskeleton looks like a series of connected hexagons," said Dr. Tsang. "If a cell loses this structure, it loses its ability to function."

The researchers also found that MFRP works in tandem with another gene, CTRP5, and that a balance between the two genes is required for normal actin regulation.

In the next phase of the study, the CUMC team used adeno-associated viruses (AAVs) to introduce normal copies of MFRP into the iPS-derived retinal cells, successfully restoring the cells' function. The researchers also used gene therapy to "rescue" mice with RP due to MFRP mutations. According to Dr. Tsang, the mice showed long-term improvement in visual function and restoration of photoreceptor numbers.

"This study provides both in vitro and in vivo evidence that vision loss caused by MFRP mutations could potentially be treated through AAV gene therapy," said coauthor Dieter Egli, PhD, an assistant professor of developmental cell biology (in pediatrics) at CUMC, who is also affiliated with the New York Stem Cell Foundation.

Dr. Tsang thinks this approach could also be used to study other forms of RP. "Through genome-sequencing studies, hundreds of novel genetic spelling mistakes have been associated with RP," he said. "But until now, we've had very few ways to find out whether these actually cause the disease. In principle, iPS cells can help us determine whether these genes do, in fact, cause RP, understand their function, and, ultimately, develop personalized treatments."


'/>"/>

Contact: Lucky Tran
lt2549@cumc.columbia.edu
212-305-3689
Columbia University Medical Center
Source:Eurekalert  

Related biology news :

1. Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
2. Stem cells can repair a damaged cornea
3. Scientists produce eye structures from human blood-derived stem cells
4. Study demonstrates cells can acquire new functions through transcriptional regulatory network
5. Epigenetic signatures direct the repair potential of reprogrammed cells
6. Researchers print live cells with a standard inkjet printer
7. Nanopills release drugs directly from the inside of cells
8. Protein jailbreak helps breast cancer cells live
9. Newly found protein helps cells build tissues
10. BU researchers derive purified lung and thyroid progenitors from embryonic stem cells
11. Housekeeping mechanism for brain stem cells discovered
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Patient-specific stem cells and personalized gene therapy
(Date:3/10/2016)... 2016   Unisys Corporation (NYSE: UIS ) ... (CBP) is testing its biometric identity solution at the Otay ... to help identify certain non-U.S. citizens leaving the country. ... to help determine the efficiency and accuracy of using biometric ... will run until May 2016. --> the ...
(Date:3/3/2016)... March 3, 2016  FlexTech, a SEMI Strategic Association ... Innovation, Research & Development, Leadership in Education, and, in ... the 9 th year of the FLEXI Awards ... and individuals from past years . Judging was ... pre-described set of criteria, by a panel of non-affiliated, ...
(Date:3/1/2016)... March 1, 2016 ... addition of the  "Global Biometric Access ... to their offering. --> ... of the  "Global Biometric Access Control ... their offering. --> Research ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... ReportsnReports.com adds 2016 global ... on US, EU, China ... healthcare business intelligence collection of its growing online ... on the Flow Cytometry market spread across 153 ... tables and figures is now available at ...
(Date:4/26/2016)... ... 26, 2016 , ... BaseHealth , the comprehensive predictive ... as Chief Business Officer. Arianpour, a genomics pioneer and visionary commercial leader with ... recently Chief Commercial Officer of Pathway Genomics. He has held senior executive roles ...
(Date:4/26/2016)... ... 26, 2016 , ... Heidelberg Instruments, a leader in design, ... its Volume Pattern Generator (VPG) line of lithography systems. The breakthrough VPG+ system ... as a solution for mid volume direct write lithography applications. It utilizes ...
(Date:4/26/2016)... ... April 26, 2016 , ... This unique "Fertility Happy Hour" event will ... an opportunity to get the lowdown on female fertility and the reproductive technologies that ... Jesse Hade, of Boston IVF - The Arizona Center, will give a short presentation ...
Breaking Biology Technology: